Be A Freedom Fighter · Bill Library
HR 10763 — Know Your Risk Act
Freedom score: -2 (scale −10 to +10)
- Individual rights: 0
- Property rights: 0
- Economic freedom: -1
- Privacy & due process: 0
- Government power: -1
Sponsor: Rep. Letlow, Julia [R-LA-5] · Latest action: Referred to the House Committee on Energy and Commerce. (2026-10-06)
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 6 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 1 — Short title. No independent effect See in text ↓
- Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves See in text ↓
- Sec. 3(a) · Government Power — HHS report. Secretary must report to Congress within 180 days on inaccuracies, utilization gaps, and factors behind them See in text ↓
- Sec. 3(b) · Government Power — Plans, not immediate creation. The report must outline planning and consensus strategies for a single publicly accessible comprehensive risk-assessment tool; the section does not itself establish that tool, require patients to enroll, or require universal individual data submission See in text ↓
- Sec. 4(a) — k grant purposes. Modifies the federal breast/cervical-cancer prevention grant statute to include evidence-based breast-cancer risk assessments, validated model training, standardized tools in appropriate clinical settings, EHR integration, public education and research/quality work as grant-program purposes/requirements. This is grant-conditioned conduct, not a compulsory screening mandate on all women or health providers See in text ↓
- Sec. 4(b) — State-grantee reporting. Requires grant-supported programs to give HHS aggregated counts/metrics on assessments, elevated risk, referrals, follow-up and disparities, with additional reports that the Secretary may require. No unqualified transfer of personally identifiable medical records is spelled out; data safeguards nevertheless depend on implementation See in text ↓
Full text (introduced version)
26 of 32 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE.
Sec. 1 — Short title. No independent effect
SEC. 2. FINDINGS.
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
Sec. 2 — Congressional findings. Identifies shortcomings and disparate performance among existing breast-cancer risk assessment tools and potential AI approaches. Statements of perceived need are not regulatory mandates by themselves
SEC. 3. REPORT ON BREAST CANCER RISK ASSESSMENT TOOLS.
Sec. 3(a) · Government Power — HHS report. Secretary must report to Congress within 180 days on inaccuracies, utilization gaps, and factors behind them
Sec. 3(a) · Government Power — HHS report. Secretary must report to Congress within 180 days on inaccuracies, utilization gaps, and factors behind them
Sec. 3(a) · Government Power — HHS report. Secretary must report to Congress within 180 days on inaccuracies, utilization gaps, and factors behind them
Sec. 3(a) · Government Power — HHS report. Secretary must report to Congress within 180 days on inaccuracies, utilization gaps, and factors behind them
Sec. 3(b) · Government Power — Plans, not immediate creation. The report must outline planning and consensus strategies for a single publicly accessible comprehensive risk-assessment tool; the section does not itself establish that tool, require patients to enroll, or require universal individual data submission
Sec. 3(b) · Government Power — Plans, not immediate creation. The report must outline planning and consensus strategies for a single publicly accessible comprehensive risk-assessment tool; the section does not itself establish that tool, require patients to enroll, or require universal individual data submission
Sec. 3(b) · Government Power — Plans, not immediate creation. The report must outline planning and consensus strategies for a single publicly accessible comprehensive risk-assessment tool; the section does not itself establish that tool, require patients to enroll, or require universal individual data submission
Sec. 3(b) · Government Power — Plans, not immediate creation. The report must outline planning and consensus strategies for a single publicly accessible comprehensive risk-assessment tool; the section does not itself establish that tool, require patients to enroll, or require universal individual data submission
SEC. 4. BREAST CANCER RISK ASSESSMENT REQUIREMENT IN GRANT PROGRAMS.
Sec. 4(a) — k grant purposes. Modifies the federal breast/cervical-cancer prevention grant statute to include evidence-based breast-cancer risk assessments, validated model training, standardized tools in appropriate clinical settings, EHR integration, public education and research/quality work as grant-program purposes/requirements. This is grant-conditioned conduct, not a compulsory screening mandate on all women or health providers
Sec. 4(a) — k grant purposes. Modifies the federal breast/cervical-cancer prevention grant statute to include evidence-based breast-cancer risk assessments, validated model training, standardized tools in appropriate clinical settings, EHR integration, public education and research/quality work as grant-program purposes/requirements. This is grant-conditioned conduct, not a compulsory screening mandate on all women or health providers
Sec. 4(a) — k grant purposes. Modifies the federal breast/cervical-cancer prevention grant statute to include evidence-based breast-cancer risk assessments, validated model training, standardized tools in appropriate clinical settings, EHR integration, public education and research/quality work as grant-program purposes/requirements. This is grant-conditioned conduct, not a compulsory screening mandate on all women or health providers
Sec. 4(b) — State-grantee reporting. Requires grant-supported programs to give HHS aggregated counts/metrics on assessments, elevated risk, referrals, follow-up and disparities, with additional reports that the Secretary may require. No unqualified transfer of personally identifiable medical records is spelled out; data safeguards nevertheless depend on implementation
Findings source: bill-scores-v2-batch46-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.